Valuation : BLS Pharmaceuticals Limited

Market Cap 213M 153M 132M 124M 113M 212M 14.61B 1.47B 572M 7.38B 574M 561M 24.45B P/E 2024
-0.72x
P/E 2025 17.8x
Enterprise Value 207M 148M 128M 120M 109M 206M 14.19B 1.42B 555M 7.16B 557M 545M 23.75B EV / Sales 2024
1.03x
EV / Sales 2025 2.82x
Free-Float
45.27%
Yield 2024 *
-
Yield 2025 -
Manager TitleAgeSince
Chief Executive Officer - 2023-05-18
Director of Finance/CFO 72 2016-08-31
Chief Operating Officer - -
Director TitleAgeSince
Chairman 67 2012-12-04
Director/Board Member 72 2022-06-29
Director/Board Member - 2023-05-18
Change 5-day change 1-year change 3-year change Capi.($)
-.--%-.--% - - 150M
-0.78%-1.42%+2.49%+22.78% 51.14B
-5.93%-0.80%+442.17%+544.09% 47.4B
-0.04%+0.73%+38.67%+18.00% 43.19B
-1.57%-2.20%+22.91%+81.22% 42.35B
-0.31%-1.75%+17.23%+52.37% 33.23B
-1.37%-2.93%+27.41%+130.30% 17.07B
-1.18%-2.41% - - 16.38B
-0.88%-0.66%+11.60%+27.75% 14.76B
-1.36%-1.11%+78.84%+46.86% 14.15B
Average -1.31%+0.70%+80.17%+115.42% 31.07B
Weighted average by Cap. -1.66%+1.12%+98.96%+137.53%

Financials

2024 2025
Net sales 9.64M 6.92M 5.96M 5.59M 5.1M 9.61M 661M 66.31M 25.87M 334M 25.97M 25.41M 1.11B 29.28M 21.01M 18.1M 16.97M 15.49M 29.19M 2.01B 201M 78.57M 1.01B 78.87M 77.16M 3.36B
Net income -13.33M -9.56M -8.24M -7.72M -7.05M -13.28M -914M -91.64M -35.75M -461M -35.89M -35.11M -1.53B 4.9M 3.52M 3.03M 2.84M 2.59M 4.89M 336M 33.71M 13.15M 170M 13.2M 12.92M 563M
Net Debt -318K -228K -196K -184K -168K -317K -21.78M -2.18M -852K -10.99M -855K -837K -36.45M -6.13M -4.4M -3.79M -3.56M -3.25M -6.11M -421M -42.19M -16.46M -212M -16.52M -16.16M -704M
Logo BLS Pharmaceuticals Limited
BLS Pharmaceuticals Limited, formerly Bioxyne Limited, is an Australia-based international consumer health and pharmaceutical company. The Company is focused on health and wellness products, psychotropic and investigational medicines. The Company operates through three segments: Wholesale PCC/USA, Consumer Health Products UK/ EU/JPN, and Pharmaceuticals AUS. Its subsidiary, Breathe Life Sciences (BLS) manufactures, commercializes, and distributes plant-based wellness products and supplements, including cannabidiol (CBD), cannabis extracts, vitamins, manuka honey, skin care products and mushroom complexes. BLS operates in Australia, the United Kingdom, Japan, and Europe with four accredited manufacturing facilities across four countries: Japan, Australia, the United Kingdom, and Czechia. The Company directs the sales arm and has developed a range of functional food products containing ingredients sourced exclusively from New Zealand and sold in Asia.
Employees
-

Annual profits - Rate of surprise